Merck, Genzyme, Alnylam play RNA musical chairs

Share this article:

Alnylam, Merck and Sanofi's Genzyme division played a bit of RNA musical chairs over the weekend, centering on Alnylam's pipeline.

Among the moves of note: Sunday's news that Merck sold Sirna Therapeutics to Alnylam, which will add RNAi therapies and siRNA-conjugates to Alnylam's portfolio of fully owned assets. Merck gets $175 million from the deal, as well as up to $105 million in development and sales milestones and a single-digit cut of royalties for some candidates Merck had a hand in developing.

Meanwhile, Sanofi announced Monday that it put $700 million toward Alnylam's pipeline, which will give Sanofi's Genzyme division “significant rights to Alnylam's portfolio of clinical and pre-clinical stage drug candidates.”

Alnylam and Genzyme paired up in 2012 to develop patisiran for the rare disease transthyretin familial amyloid polyneuropathy. Monday's news gives Genzyme greater rights to this drug, the right to commercialize three Alnylam pipepline items, and the option to develop and commercialize all rare genetic-disease drugs outside of North America and Western Europe until 2020.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.